Purpose: To improve the outcomes of patients with T-cell acute lymphoblastic
leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome
inhibitor bortezomib was examined in the Children’s Oncology Group phase
III clinical trial AALL1231, which also attempted to reduce the use of
prophylactic cranial radiation (CRT) in newly diagnosed T-ALL.